Abstract
The chemosensitizing potency of dexniguldipine hydrochloride (B8509-035) on epidoxorubicin was assessed in a multidrug-resistant (MDR) tumour model, the intrinsic MDR rat colon carcinoma CC531. In vitro in the sulphorhodamine B cell-viability assay the cytotoxicity of epidoxorubicin was increased approximately 15-fold by co-incubation with 50 ng/ml dexniguldipine. In vivo concentrations of dexniguldipine 5 h after a single oral dose of 30 mg/kg were 72 (±19 SD) ng/ml in plasma and 925 (±495 SD) ng/g in tumour tissue. Levels of the metabolite of dexniguldipine, M-1, which has the same chemosensitizing potential, were 26 (±6 SD) ng/ml and 289 (±127 SD) ng/g respectively. The efficacy of treatment with 6 mg/kg epidoxorubicin applied intravenously combined with 30 mg kg−1 day−1 dexniguldipine administered orally for 3 days prior to epidoxorubicin injection was evaluated on tumours grown under the renal capsule. Dexniguldipine alone did not show antitumour effects in vivo. Dexniguldipine modestly, but consistently, potentiated the tumour-growth-inhibiting effect of epidoxorubicin, reaching statistical significance in two out of four experiments. In conclusion, these experiments show that dexniguldipine has potency as an MDR reverter in vitro and in vivo in this solid MDR tumour model.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- MDR :
-
multidrug resistance
- PBS :
-
phosphate-buffered saline
References
Bellamy WT, Dalton WS (1994) Multidrug resistance in the laboratory and clinic. Adv Clin Chem 31:1–61
Boss H, Eisenhauer S, Ise W, Gekeler V, Sanders K-H (1994) Dexniguldipine-HCl modulates the MDR1 mediated drug resistance in a nude mouse xenograft model (abstract). Anti-Cancer Drugs 5 [Suppl 1]:29
De Greef C, Van der Heyden S, Viana F, Eggermont J, De Bruijn EA, Raeymaekers L, Droogmans G, Nilius B (1995) Lack of correlation betweenmdr-1 expression and volume activation of chloride-currents in rat colon cancer cells. Pflugers Arch 430:296–298
Echizen H, Brecht T, Niedergesäss S, Vogelgesang B, Eichelbaum M (1985) The effect of dextro-, levo-, and racemic verapamil on atrioventricular conduction in humans. Am Heart J 109:210–217
Gheuens E, Van der Heyden S, Elst H, Eggermont A, Van Oosterom A, De Bruijn E (1993) Multidrug resistance in rat colon carcinoma cell lines CC531, CC531mdr+ and CC531rev. Jpn J Cancer Res 84:1201–1208
Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I (1989) Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81:116–124
Hill BT, Hosking LK (1994) Differential effectiveness of a range of novel drug-resistance modulators, relative to verapamil, in influencing vinblastine or teniposide cytotoxicity in human lymphoblastoid CCRF-CEM sublines expressing classic or atypical multidrug resistance. Cancer Chemother Pharmacol 33:317–324
Hofmann J, Ueberall F, Egle A, Grunicke H (1991) B-859-35, a new drug with anti-tumour activity reverses multi-drug resistance. Int J Cancer 47:870–874
Hofmann J, Wolf A, Spitaler M, Böck G, Drach J, Ludescher C, Grunicke H (1992) Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine. J Cancer Res Clin Oncol 118:361–366
Höllt V, Kouba M, Dietel M, Vogt G (1992) Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. Biochem Pharmacol 43:2601–2608
Marquet RL, Westbroek DL, Jeekel J (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumour site. Int J Cancer 33:689–692
Niwa K, Yamada K, Furukawa T, Shudo N, Seto K, Matsumoto T, Takao S, Akiyama S-i, Shimazu H (1992) Effect of a dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorian-2-yl)-1-(2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate on reversing in vivo resistance of tumour cells to Adriamycin. Cancer Res 52:3655–3660
Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE (1991) Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105–110
Plumb JA, Milroy R, Kaye SB (1990) The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 39:787–792
Reymann A, Looft G, Woermann C, Dietel M, Erttmann R (1993) Reversal of multidrug resistance in Friend leukemia cells by dexniguldipine-HCl. Cancer Chemother Pharmacol 32:25–30
Roller E, Klumpp B, Krause J, Eichelbaum M, Schumacher K (1993) Influence of sequential exposure to R-verapamil or B8509-035 on rhodamine 123 accumulation in human lymphoblastoid cell lines. Cancer Chemother Pharmacol 32:151–155
Scheulen ME, Meusers P, Schröder J, Uppenkamp M, Müller M, Reiter WW, Weimar Ch, Rathgeb F, Brittinger G, Seeber S (1995) Phase I/II trial of additive dexniguldipine (hADM) in acute myeloid leukemia (AML) refractory to previous daunorubicin and high-dose cytarabine (hAD) (abstract). Proc Am Assoc Cancer Res 36:203
Schüller HM, Correa E, Orloff M, Reznik GK (1990) Succesful chemotherapy of experimental neuroendocrine lung tumours in hamsters with an antagonist of Ca2+/calmodulin. Cancer Res 50:1645–1649
Schüller HM, Orloff M, Reznik GK (1991) Antiproliferative effects of the Ca2+/calmodulin antagonist B859-35 and the Ca2+-channel blocker verapamil on human lung cancer cell lines. Carcinogenesis 12:2301–2303
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107–1112
Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Löwenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255–259
Sonneveld P, Schoester M, De Leeuw K (1994) Clinical modulation of multi-drug resistance in multiple myeloma: effect of cyclosporine on resistant tumour cells. J Clin Oncol 12:1584–1591
Thaler J, Reiter WW, Ludescher C, Wörmann B, Ramsauer B, Nüßler V, Reiber C, Weimar C, Nowrousian MR (1994) Modulation of multidrug resistance (MDR1) by dexniguldipine in combination with VAD or VECD in patients with refractory myeloma (abstract). Onkologie 17 [Suppl 2]: abstract 603
Ukena D, Boewer C, Oldenkott B, Rathgeb F, Wurst W, Zech K, Sybrecht GW (1995) Tolerance, safety, and kinetics of the new antineoplastic compound dexniguldipine-HCl after oral administration: a phase I dose-escalation trial. Cancer Chemother Pharmacol 36:160–164
Van de Vrie W, Gheuens EEO, Durante NMC, De Bruijn EA, Marquet RL, Van Oosterom AT, Eggermont AMM (1993) In vitro and in vivo chemosensitizing effect of cyclosporin A on an intrinsic multidrug-resistant rat colon tumour. J Cancer Res Clin Oncol 119:609–614
Van de Vrie W, Jonker AM, Marquet RL, Eggermont AMM (1994) The chemosensitizer cyclosporin A enhances the toxic side-effects of doxorubicin in the rat. J Cancer Res Clin Oncol 120:533–538
Zech K, Herzog R (1991) Two-dimensional high-performance liquid chromatography at low ng/ml levels of the anti-proliferative agent B859-35 in serum with automated sample clean-up, solidphase trapping and ultraviolet detection. J Chromatogr 553:55–63
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Van de Vrie, W., Eggermont, A.M.M., Durante, N.M.C. et al. Modulation of multidrug resistance with dexniguldipine hydrochloride (B8509-035) in the CC531 rat colon carcinoma model. J Cancer Res Clin Oncol 122, 403–408 (1996). https://doi.org/10.1007/BF01212879
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01212879